Table 3.

Currently available drugs and their indications for advanced solid tumors passing the postulated OS threshold values for the mCMO in the 43 pivotal trials analyzed: “SMALL”

Level of required benefitPrognostic groupDrugs meeting both criteria of median gain and HR for OSDrugs meeting either criteria of median gain or HR for OS
High<9 moCetuximab-colon (30)Temsirolimus-kidney (MG; ref. 6); Ipilimumab-melanoma (MG; ref. 40); Cetuximab-colon (HR +MG; ref. 30)
9–12 moAbiraterone-prostate (MG; ref. 42)
12–18 moEnzalutamide-prostate (HR; ref. 44)
>18 moBevacizumab-ovarian (46)Tdm1-breast (HR; ref. 15); Cetuximab-head and neck (MG; ref. 38); Bevacizumab-ovarian (HR +MG; ref. 46)
Medium<9 moCetuximab-colon (30)Sorafenib-HCC (ref. 37); Temsirolimus-kidney (MG; ref. 6); Ipilimumab-melanoma (MG; ref. 40); Cetuximab-colon (HR +MG; ref. 30)
9–12 moVemurafenib-melanoma (39); Radium223-prostate (45)Vemurafenib-melanoma (HR +MG; ref. 39); Radium223-prostate (HR +MG; ref. 45); Abiraterone-prostate (MG; ref. 42)
12–18 moEnzalutamide-prostate (44); Bevacizumab-colon (23)Cabazitaxel-prostate (HR; ref. 43); Bevacizumab-colon (MG; ref. 26); Bevacizumab-colon (HR +MG; ref. 23); Sorafenib-kidney (MG; ref. 49); Enzalutamide-prostate (HR +MG; ref. 44)
>18 moTdm1-breast (15); Bevacizumab-ovarian (46); Cetuximab-head and neck (38)Bevacizumab-ovarian (HR +MG; ref. 46); Panitumumab-colon (MG; ref. 29); Sunitinib-kidney (MG; ref. 7); Trastuzumab-breast (MG; ref. 12); Tdm1-breast (HR +MG; ref. 15); Cetuximab-head and neck (HR +MG; ref. 38)
Low<9 moErlotinib-lung (17); Cetuximab-colon (30); Ipilimumab-melanoma (40); Sorafenib-hcc (37)Erlotinib-lung (HR +MG; ref. 17); Temsirolimus-kidney (MG; ref. 6); Sorafenib-HCC (HR +MG; ref. 37); Ipilimumab-melanoma (HR +MG; ref. 40); Cetuximab-colon (HR +MG; ref. 30)
9–12 moAbiraterone-prostate (42); Vemurafenib-melanoma (39); Trastuzumab-gastric (41); Radium223-prostate (45)Radium223-prostate (HR +MG; ref. 45); Vemurafenib-melanoma (HR +MG; ref. 39); Bevacizumab-colon (HR; ref. 25); Trastuzumab-gastric (HR +MG; ref. 41); Abiraterone-prostate (HR +MG; ref. 42)
12–18 moBevacizumab-colon (23); Bevacizumab-colon (24) Enzalutamide-prostate (44)Cabazitaxel-prostate (HR; ref. 43); Bevacizumab-colon (MG; ref. 26); Bevacizumab-colon (HR +MG; ref. 24); Sorafenib-kidney (MG; ref. 49); Enzalutamide-prostate (HR +MG; ref. 44); Bevacizumab-colon (HR +MG; ref. 23)
>18 moTrastuzumab-breast (12); Tdm1-breast (15); Bevacizumab-ovarian (46) Cetuximab-head and neck (38)Bevacizumab-ovarian (HR +MG; ref. 46); Tdm1-breast (HR +MG; ref. 15); Cetuximab-head and neck (HR +MG; ref. 38); Panitumumab-colon (MG; ref. 29); Sunitinib-kidney (MG; ref. 7); Cetuximab-colon (MG; ref. 31); Trastuzumab-breast (HR +MG; ref. 12)

Abbreviation: MG, median gain next to each agent indicates which specific parameter of SMALL was met in each trial.